Assembly Biosciences (NASDAQ:ASMB) Rating Lowered to Hold at StockNews.com

Assembly Biosciences (NASDAQ:ASMB) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Monday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research report on Monday.

Assembly Biosciences Stock Performance

Shares of NASDAQ ASMB opened at $11.42 on Monday. The business’s 50-day simple moving average is $12.77 and its 200-day simple moving average is $15.05. Assembly Biosciences has a 52 week low of $10.27 and a 52 week high of $19.93. The firm has a market cap of $72.59 million, a price-to-earnings ratio of -1.70 and a beta of 0.62.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.75) by $0.18. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The company had revenue of $7.36 million for the quarter, compared to the consensus estimate of $7.05 million. As a group, equities research analysts forecast that Assembly Biosciences will post -6.87 earnings per share for the current year.

Insider Activity at Assembly Biosciences

In other Assembly Biosciences news, Director Michael Houghton purchased 3,202 shares of the stock in a transaction on Monday, December 30th. The shares were purchased at an average price of $15.61 per share, with a total value of $49,983.22. Following the acquisition, the director now directly owns 3,202 shares of the company’s stock, valued at $49,983.22. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Assembly Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in ASMB. Gilead Sciences Inc. acquired a new position in Assembly Biosciences in the fourth quarter worth about $34,865,000. Peapod Lane Capital LLC bought a new stake in Assembly Biosciences during the 4th quarter worth approximately $994,000. B Group Inc. acquired a new stake in Assembly Biosciences during the 4th quarter valued at $799,000. Monimus Capital Management LP bought a new position in Assembly Biosciences in the 4th quarter valued at $664,000. Finally, Renaissance Technologies LLC boosted its stake in Assembly Biosciences by 44.3% in the fourth quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock worth $1,495,000 after purchasing an additional 29,087 shares in the last quarter. 19.92% of the stock is owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.